                         SEQUENCE LISTING

<110>  DiMarchi, Richard
 
<120>  Glucagon/GLP-1 Receptor Co-Agonists

<130>  31135/46342 PCT

<150>  US-61/500,027
<151>  2011-06-22

<150>  US-61/547,360
<151>  2011-10-14

<160>  22    

<170>  PatentIn version 3.5

<210>  1
<211>  29
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<223>  Native human glucagon

<400>  1

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  2
<211>  37
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<223>  GLP-1

<400>  2

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 
1               5                   10                  15      


Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu 
            20                  25                  30          


Val Lys Gly Arg Gly 
        35          


<210>  3
<211>  33
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<223>  GLP-2

<400>  3

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  4
<211>  37
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<223>  Oxyntomodulin

<400>  4

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr Lys Arg Asn 
            20                  25                  30          


Arg Asn Asn Ile Ala 
        35          


<210>  5
<211>  30
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<223>  GLP1 (7-36 amide)

<220>
<221>  MOD_RES
<222>  (30)..(30)
<223>  C-terminal amidation

<400>  5

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 
            20                  25                  30  


<210>  6
<211>  31
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<223>  GLP-1 (7-37 acid)

<400>  6

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly 
            20                  25                  30      


<210>  7
<211>  39
<212>  PRT
<213>  Heloderma suspectum


<220>
<221>  MISC_FEATURE
<223>  Exendin-4

<400>  7

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


<210>  8
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  8

Lys Arg Asn Arg Asn Asn Ile Ala 
1               5               


<210>  9
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  9

Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser 
1               5                   10  


<210>  10
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  10

Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser 
1               5                   10      


<210>  11
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  11

Lys Arg Asn Arg 
1               


<210>  12
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu 
       spacer

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is AIB

<220>
<221>  MOD_RES
<222>  (31)..(31)
<223>  Xaa is gamma-Glu

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  C-terminal amidation

<400>  12

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr Lys Xaa 
            20                  25                  30      


<210>  13
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  Covalently bound to PEG

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa is gamma-Glu

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  C-terminal amidation

<400>  13

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Arg Ala Xaa Glu Phe Val Cys Trp Leu Leu Asp Thr Lys Xaa 
            20                  25                  30      


<210>  14
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  D-Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa is gamma-Glu

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  C-terminal amidation

<400>  14

His Ser Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr Lys Xaa 
            20                  25                  30      


<210>  15
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu 
       spacer

<220>
<221>  MOD_RES
<222>  (16)..(16)
<223>  Xaa is AIB

<220>
<221>  MOD_RES
<222>  (27)..(27)
<223>  Xaa is Methionine sulfoxide

<400>  15

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Xaa Asp Thr Lys Gln 
            20                  25                  30      


<210>  16
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu 
       spacer

<220>
<221>  MOD_RES
<222>  (16)..(16)
<223>  Xaa is AIB

<400>  16

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr Lys Gln 
            20                  25                  30      


<210>  17
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu 
       spacer

<220>
<221>  MOD_RES
<222>  (16)..(16)
<223>  Xaa is AIB

<220>
<221>  MOD_RES
<222>  (31)..(31)
<223>  Xaa is gamma-Glu

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  C-terminal amidation

<400>  17

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Xaa 
            20                  25                  30      


<210>  18
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu 
       spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amidation

<400>  18

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Asp Thr 
            20                  25                  


<210>  19
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  D-Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amidation

<400>  19

His Ser Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  20
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu 
       spacer

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is AIB

<220>
<221>  MOD_RES
<222>  (31)..(31)
<223>  D-Glu

<400>  20

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Lys Thr Lys Glu 
            20                  25                  30      


<210>  21
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<223>  Liraglutide

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu spacer

<400>  21

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 
            20                  25                  30      


<210>  22
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is AIB

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Acylated with a C16 fatty acyl group via gamma-Glu-gamma-Glu 
       spacer

<220>
<221>  MOD_RES
<222>  (16)..(16)
<223>  Xaa is AIB

<220>
<221>  MOD_RES
<222>  (28)..(28)
<223>  Xaa is Orn

<400>  22

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Met Xaa Asp Thr Lys Gln 
            20                  25                  30          


